Plasma adiponectin in overweight, nondiabetic individuals with or without insulin resistance

Diabetes, Obesity and Metabolism

Volumn 5, Issue 5, 2003, Pages 349-353

  Shand, B I ^a   Scott, Russell S ^a   Elder, P A ^b   George, P M ^b  

^a CHRISTCHURCH HOSPITAL   (New Zealand)

^b CANTERBURY HEALTH LABORATORIES   (New Zealand)

Author keywords

Adipocytes; Adiponectin; Inflammatory markers; Insulin resistance; Obesity; Type 2 diabetes dyslipidaemia

Indexed keywords

ADIPONECTIN; APOLIPOPROTEIN A1; C REACTIVE PROTEIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LEPTIN; LIPID;

ADIPOCYTE; ADULT; AGE; ANTHROPOMETRY; ARTICLE; ATHEROGENESIS; BODY FAT; BODY MASS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; DEMOGRAPHY; DIABETES MELLITUS; DIET RESTRICTION; DISEASE MARKER; FEMALE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; OBESITY; PREVALENCE; PROTEIN ANALYSIS; PROTEIN SYNTHESIS; RADIOIMMUNOASSAY; SEX DIFFERENCE;

EID: 0141539501     PISSN: 14628902     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1463-1326.2003.00279.x     Document Type: Article

References (12)

1. Weyer C, Funahashi T, Tanaka S et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001; 86: 1930-1935.
2. Arita Y, Kihara S, Ouchi N et al. Paradoxical decrease of an adipose-specific protein, adiponectin in obesity. Biochem Biophys Res Commun 1999; 257: 79-83.
3. Kazumi T, Kawaguchi A, Sakai K, Hirano T, Yoshino G. Young men with high-normal blood pressure have lower serum adiponectin, small LDL size, and higher elevated heart rate than those with optimal blood pressure. Diabetes Care 2002; 25: 971-976.
4. Yamamoto Y, Hirose H, Saito I, Saruta T. Correlation of adipocyte-derived protein, adiponectin with insulin resistance index and serum HDL-cholesterol, independent of body mass index in the Japanese population. Diabetes 2002; 51 (Suppl. 2): A307.
5. Executive summary of the third report of the National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. JAMA 2001; 285: 2486-2497.
6. Rudenski AS, Matthews DR, Levy JC, Turner RC. Understanding insulin resistance: both glucose resistance and insulin resistance are required to model human diabetes. Metabolism 1991; 40: 908-917.
7. McAuley KA, Williams SM, Mann JI et al. Diagnosing insulin resistance in the general population. Diabetes Care 2001; 24: 460-464.
8. Hotta K, Funahashi T, Arita Y et al. Plasma concentrations of a novel, adipose specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000; 20: 1595-1599.
9. Stefan N, Vozarova B, Funahashi T et al. Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans. Diabetes 2002; 50: 1884-1888.
10. Spranger J, Kroke A, Möhlig M et al. Adiponectin and protection against type 2 diabetes mellitus. Lancet 2003; 361: 226-228.
11. Ryan AS, Berman DM, Nicklas BJ, Gingerich GS, Meneilly JM, Egan DE. Relationship between plasma adiponectin levels, body composition and glucose utilization across the adult age span. Diabetes 2002; 51 (Suppl. 2): A405.
12. Zoccali C, Mallamaci F, Tripepi G et al. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 2002; 13: 134-141.